Analysis of the Sensitivity to Endocrine Therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (AFT-05).
   Google Scholar   
Citation:
J Clin Oncol vol 24 (16_suppl) 538
Meeting Instance:
ASCO 2024
Year:
2024
Type:
Abstract
Sub type:
Poster General
Funding:
AFT
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Pfizer  
Grants:
AFT, ABCSG, Pfizer, ECOG-ACRIN, NSABP Foundation, GBG, BIG  
Corr. Author:
 
Authors:
                                         
Networks:
LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-TX035   
Study
AFT-05
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: